CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Vaccinex, Inc. (VCNX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Vaccinex, Inc. (VCNX)

Pharmaceutical Preparations · market cap $3M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
10
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Vaccinex, Inc. (VCNX) is a micro-cap (about $2M market cap, ~2.68M shares, ~$0.82) with 23 employees. Our database lists a broad pipeline led by an 11-valent HPV vaccine in Phase 3, alongside oncology, neurology and other vaccine programs. The financial setup is the dominant fact: $1.1M cash and a computed runway of 0.2 months.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Avelumab and PepinemabPhase 2Metastatic Pancreatic Adenocarcinoma
VX15/2503 + avelumabPhase 2Carcinoma, Non-Small-Cell Lung
pepinemab + pembrolizumabPhase 2Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
VX15/2503Phase 2Huntington's Disease
PepinemabPhase 2Alzheimer Disease
2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)Phase 3Human Papillomavirus (HPV) Infection
SARS-CoV-2 (LVRNA009) groupPhase 2SARS-CoV-2
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)Phase 2COVID-19
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)Phase 3HPV InfectioN
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)Phase 3Norovirus Infections
Price & technical context
3-month
+28.2%
6-month
-9.1%
12-month
+100.0%
52-wk range
$0.48–$1.49
vs 50-day MA
+4.7%
vs 200-day MA
-1.5%
Realized vol
204.8%
Max drawdown
-92.6%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for VCNX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.